American Society of Hematology

ASH is committed to helping practicing hematologists provide quality care to patients, continue their professional development, and enhance their knowledge and expertise.

Guidelines and Quality Care

Resources to help practitioners improve the quality of hematologic care provided to patients

Professional Development

Resources to support hematologists with both continuing medical education and maintaining board certification

  • Drug Resources

    Newly approved therapies and updates on shortages of hematologic drugs

  • Consult a Colleague

    Service that provides advice on clinical questions in one to two days

  • Policy Resources

    Information on federal programs and policies affecting clinical practice

View all Ask the Hematologist
  • FDA Approves an Oral Suspension of mercaptopurine

    On April 28, 2014, the U. S. Food and Drug Administration approved an oral suspension of mercaptopurine (Purixan ®, NOVA Laboratories Limited). Mercaptopurine is a 20 mg/ml oral suspension. Purixan is indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination regimen.

  • FDA Approves ofatumumab for Chronic Lymphocytic Leukemia

    On April 17, 2014, the U. S. Food and Drug Administration approved ofatumumab (Arzerra Injection, for intravenous infusion; GlaxoSmithKline) in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.

  • FDA Approves Ibrutinib to Treat Chronic Lymphocytic Leukemia

    FDA Approves Ibrutinib to Treat Chronic Lymphocytic Leukemia In collaboration with the Food and Drug Administration (FDA), and as a service to our members, ASH provides information about newly approved therapies and other important FDA actions (e.g., updated safety information, ne

  • FDA Approves Ibrutinib for Mantle Cell Lymphoma

    On November 13, 2013, the U. S. Food and Drug Administration granted accelerated approval to Ibrutinib (IMBRUVICA, Pharmacyclics, Inc.) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

View all FDA alerts
View all policy news
back to top